A study to assess the rate of occurence of nausea and vomiting followed by the addition of the drug morphine given as apart of anaesthesia for patients with carcinoma cervix undergoing high dose (HDR) intracavitary brachytherapy.
Not Applicable
- Conditions
- Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
- Registration Number
- CTRI/2020/06/025687
- Lead Sponsor
- Christian MedicalCollegeVellore
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Histologically proven carcinoma cervix for
intracavitary brachytherapy.
2) ASA I/II
3) Consent for participation in study
Exclusion Criteria
1) Patient undergoing treatment for chronic
pain
2) Preoperative history of nausea and vomiting
requiring treatment
3) Unfit for spinal anaesthesia like
Coagulopathy, cardiac lesions, infection at
the site of spinal injection, fever
4) Unwilling or unable to give consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie morphine-induced nausea and vomiting in cervical cancer patients undergoing HDR brachytherapy?
How does intrathecal morphine compare to standard analgesics in pain management and emesis prevention during HDR brachytherapy for cervical cancer?
Are CYP2D6 polymorphisms or other genetic markers predictive of morphine-induced emesis risk in cervical cancer patients undergoing HDR brachytherapy?
What are the incidence rates and management strategies for morphine-related adverse events in HDR brachytherapy for cervical cancer?
Do combination therapies with antiemetics like ondansetron reduce morphine-induced nausea in cervical cancer HDR brachytherapy patients?